Skip to main content

Advertisement

Table 3 Meta-analysis evaluating the adjusted association between HBV infection and NHL subtypes and by region

From: Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma

Type overall OR High prevalence countries OR (95% CI) Intermediate prevalence countries OR (95% CI) Low prevalence countries OR (95% CI)
NHL 2.09 (1.76–2.50) (*P < 0.01) n = 35 2.20 (1.78–2.72) (P < 0.01) n = 15 2.48 (1.55–3.95) (P < 0.01) n = 10 1.64 (1.15–2.34) (P < 0.01) n = 10
DLBCL 2.15 (1.52–3.02) (P < 0.01) n = 14 2.69 (1.88–3.86) (P < 0.01) n = 6 3.38 (2.13–5.36) (P = 0.47) n = 3 1.14 (0.58–2.26) (P < 0.01) n = 5
BL 2.22 (0.87–5.66) (P < 0.01) n = 7 1.50 (0.94–2.40) (P = 0.79) n = 6 n = 0 n = 1
CLL/SLL 1.37 (0.93–2.00) (P < 0.01) n = 11 1.61 (1.00–2.58) (P = 0.09) n = 5 n = 1 1.33 (0.66–2.67) (P = 0.02) n = 5
FL 1.81 (1.12–2.94) (P < 0.01) n = 13 2.42 (1.36–4.32) (P < 0.01) n = 6 4.17 (2.06–8.46) (P = 0.71) n = 2 0.85 (0.44–1.66) (P = 0.02) n = 5
NK/T 1.30 (0.82–2.08) (P = 0.06) n = 7 1.23 (0.76–1.89) (P = 0.04) n = 5 4.51(0.56–36.25) (P = 0.57) n = 2 n = 0
PTCL 1.31 (0.89–1.91) (P = 0.44) n = 4 1.31 (0.89–1.91) (P = 0.44) n = 4 n = 0 n = 0
ALCL 3.23 (1.27–8.18) (P = 0.04) n = 3 3.23 (1.27–8.18) (P = 0.04) n = 3 n = 0 n = 0
  1. Abbreviations: NHL = non-Hodgkin lymphoma, HBV = hepatitis B virus, OR = odds ratio, CI = confidence interval, DLBCL = diffuse large B-cell lymphoma, BL = Burkitt’s lymphoma, FL = follicular lymphoma, CLL/SLL = small lymphocytic lymphoma/chronic lymphocytic leukemia, NK/T = NK/T cell lymphoma, PTCL = peripheral T-cell lymphoma, ALCL = anaplastic large cell lymphoma. * Statistically significant at the 0.05 alpha level